Skip to content

Ziprasidone

    DEA Class;  Rx

    Common Brand Names; Geodon

    • Antipsychotics, 2nd Generation; 
    • Antimanic Agents
    Oral and parenteral atypical antipsychotic; belongs to benzisoxazole/benzoisothiazol derivatives class
    Used orally in adults for schizophrenia, as monotherapy for acute episodes of bipolar I disorder, and as an adjunct to lithium or valproate for maintenance treatment of bipolar I disorder; IM injection is used in adults for acute agitation due to schizophrenia
    Has a potential for QT prolongation; as with all antipsychotics, boxed warning for increased mortality risk in elderly patients with dementia-related psychosis

    Indicated for the treatment of schizophrenia.

    For the treatment of bipolar disorder (bipolar I disorder), including monotherapy treatment of mania or mixed episodes and as an adjunct to lithium or valproate in maintenance therapy.
    For the treatment of acute agitation associated with schizophrenia or other psychiatric illness associated with acute agitation.
    For the treatment of Tourette’s syndrome or chronic tic disorders.
    For the treatment of severe behavioral or psychological symptoms of dementia (BPSD).

    Documented hypersensitivity

    Any drugs or conditions that prolong QT interval

    Recent acute myocardial infarction

    Uncompensated heart failure

    • Somnolence (11-15%)
    • Headache (11%)
    • Nausea (4-12%)
    • Extrapyramidal symptoms (2-31%)
    • Dizziness (3-16%)
    • Respiratory disorders (1-8%)
    • Constipation (2-9%)
    • Dyspepsia (1-8%)
    • Rash (4-5%)
    • Tachycardia (2%)
    • Hypoesthesia (2%)
    • Priapism (1%)
    • Orthostatic hypotension (5%)
    • Xerostomia (1-5%)
    • Anorexia (2%)
    • Myalgia (2%)
    • Rhinitis (1-4%)
    • Cough (3%)
    • Syncope
    • Seizures

    Seizure disorders; may cause hypotension, EPS, somnolence, and sensory instability, which could lead to falls and, consequently, fractures or other injuries; for patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy

    Atypical antipsychotics have been associated with metabolic changes (eg, hyperglycemia, dyslipidemia, and body weight gain) that may increase cardiovascular/cerebrovascular risk

    Hyperglycemia may occur and in some cases may be extreme, resulting in ketoacidosis, hyperosmolar coma, or death; monitor blood glucose of high-risk patients

    Neuroleptic malignant syndrome reported with antipsychotic drugs

    Tardive dyskinesia, acute dystonic reactions, pseudoparkinsonism, or akathisia may develop acutely or chronically

    Discontinue if rash develops without an identified cause

    Drug reaction with eosinophilia and systemic symptoms (DRESS) reported; DRESS consists of combination of three or more of the following: cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, lymphadenopathy and one or more systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and pericarditis; DRESS is sometimes fatal; discontinue therapy if DRESS suspected

    There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics.

    Limited data from a published case report indicate the presence of drug in human milk

    Adults

    160 mg/day PO or 40 mg/day IM.

    Geriatric

    160 mg/day PO. 40 mg/day IM is suggested from off-label use.

    Adolescents

    More than 16 years: 40 mg/day PO per Tourette’s off-label use. 20 mg/dose IM for acute agitation off-label use has been suggested.
    13 to 16 years: 40 mg/day PO per Tourette’s off-label use. 10 mg/dose IM for acute agitation off-label use has been suggested.

    Children

    12 years: 40 mg/day PO per Tourette’s off-label use. 10 mg/dose IM for acute agitation off-label use has been suggested.
    7 to 11 years: 40 mg/day PO per Tourette’s off-label use. Safety and efficacy have not been established for IM dosing.
    6 years or less: Safety and efficacy have not been established.

    Infants

    Not indicated.

    Ziprasidone hydrochloride; ziprasidone mesylate

    capsule

    • 20mg
    • 40mg
    • 60mg
    • 80mg

    powder for injection

    • 20mg